Johnson & Johnson (NYSE:JNJ) experienced an 11% price increase over the last quarter. This movement coincided with several ...

We recently published a list of Jim Cramer Focused On These 9 Stocks Recently. In this article, we are going to take a look ...

We recently published a list of 13 Best Healthcare Dividend Stocks to Invest in. In this article, we are going to take a look ...

Johnson & Johnson (NYSE:JNJ) experienced an 11% share price increase over the last quarter, coinciding with pivotal ...

We recently compiled a list of the 14 Best Performing Dividend Stocks To Buy Now. In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against the other dividend ...

Click here to discover the nuances of Johnson & Johnson with our detailed analytical report. NYSE:JNJ Revenue & Expenses Breakdown as at Mar 2025 Over the past five years, Johnson & Johnson (JNJ ...

Johnson & Johnson (NYSE:JNJ – Get Free Report) has been given an average recommendation of “Moderate Buy” by the eighteen research firms that are covering the stock, Marketbeat reports.

Johnson & Johnson Stock Up 1.9 % Shares of NYSE:JNJ opened at $157.93 on Thursday. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 0.43. Johnson ...

Johnson & Johnson (NYSE:JNJ) is one of the most prominent healthcare companies globally. The company, through its subsidiaries, develops, manufactures, and sells a diverse range of healthcare ...

Multinational healthcare company Johnson & Johnson (NYSE:JNJ) met Wall Street’s revenue expectations in Q4 CY2024, with sales up 5.3% year on year to $22.52 billion. Its non-GAAP profit of $2.04 ...

Johnson & Johnson (NYSE:JNJ) is suing Samsung Bioepis for breach of contract related to the launch of a biosimilar of J&J's blockbuster drug Stelara, also known as ustekinumab. The drug is used to ...

Johnson & Johnson (NYSE:JNJ) recently experienced a 12% price increase over the last quarter, largely driven by significant announcements regarding its clinical trials, particularly the ANTHEM-UC ...